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Abstract
Purpose—To evaluate whether levels of corneal subbasal nerve fiber length (SNFL) in dry eye 
disease (DED) could prognosticate the level of improvement in signs and symptoms after 
treatment.
Design—Phase IV, double-masked, randomized clinical trial.
Participants—Sixty patients with meibomian gland dysfunction-associated DED and 27 age-
matched controls.
Methods—Patients with DED were randomized to receive topical artificial tears, loteprednol 
etabonate 0.5%, or loteprednol etabonate 0.5%/tobramycin 0.3% twice daily for 4 weeks. At 
baseline, in vivo confocal microscopy of central cornea was performed in both eyes. Patients with 
DED were divided into 2 subgroups, those with low baseline SNFL and those with near-normal 
baseline SNFL (the cut-off point: mean SNFL in controls minus 2 standard deviations). Clinical 
signs and symptoms at baseline and after 4 weeks of treatment were compared between the 
subgroups with low and near-normal SNFL for all therapeutic groups.
Main Outcome Measures—Symptom questionnaires, corneal fluorescein staining (CFS), 
conjunctival staining with lissamine green, tear break-up time, Schirmer’s test, and SNFL.
Results—In patients with DED, baseline SNFL (17.06 ± 5.78 mm/mm2) was significantly lower 
than in controls (23.68 ± 3.42, P=0.001). In the artificial tear and loteprednol groups, although no 
significant improvement in any sign or symptom was noted in patients with low baseline SNFL 
(<16.84 mm/mm2), subjects with near-normal baseline SNFL (≥16.84 mm/mm2) showed 
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significant improvement in both symptoms and corneal fluorescein staining (CFS) score (all 
P<0.05). In the loteprednol/tobramycin group, no significant change was evident for any sign or 
symptom in either subgroup of low or near-normal baseline SNFL.
Conclusions—Significant improvements in CFS and patient symptomatology after DED 
treatment were evident only in the subgroup with near-normal corneal SNFL. Consideration of 
SNFL may thus assist in explaining the variability of patients’ response to DED therapy.
INTRODUCTION
Dry eye disease (DED) is one of the most commonly encountered conditions in ophthalmic 
practice. It is estimated that over 5–30% of the population aged 50 years or older suffer from 
DED, with a higher prevalence in some regions of the world, such as Asia.1–3 Although 
various subtypes of DED exist, such as aqueous-tear deficient and evaporative subtypes, the 
common denominator of the disease is tear film instability and ocular surface 
inflammation.4,5 This fact has clearly been reflected in the new definition of DED by Dry 
Eye WorkShop in 2007.6 Due to role of inflammation in the pathogenesis of DED, anti-
inflammatory agents are commonly used for treatment of DED,7 though with variable 
degrees of success.8,9 However, it remains unknown why not all patients with DED respond 
favorably to anti-inflammatory therapy.
The cornea is the most densely innervated tissue in the body with a nerve density of 300–
600 times that of the skin.10,11 A large number of studies have demonstrated that in addition 
to providing sensation, corneal nerves play a significant role in the maintenance of corneal 
epithelial health.11 These nerves, which promote epithelial proliferation and viability,12 have 
been shown to be reduced in a variety of ocular and systemic conditions, resulting in 
compromised ocular surface and reduced tear function.13,14 Examples include corneal 
insults such as infections, injuries, or surgeries, systemic disease like diabetes mellitus, and 
any damage to the trigeminal nerve.11,13,14 In addition to these conditions, the density of 
corneal nerves has been shown to be reduced in DED,15–22 which correlates with ocular 
surface staining.22 However, it remains unclear whether the density of corneal nerves at the 
time of treatment initiation plays any role in the therapeutic response in patients with DED.
As corneal nerves are required for the maintenance of ocular surface health,11,12 their 
trophic function may be important not only in normal conditions but also in disease states. 
Therefore, in this study we hypothesized that the response to treatment in patients with DED 
is dependent on the presence of near-normal corneal nerve density, and thus variable 
responses to DED therapy stem from different levels of corneal nerve density in each 
individual.
MATERIALS AND METHOD
Study Design and Participants
This prospective, double-masked, Phase IV randomized clinical trial included 60 patients 
with DED associated with meibomian gland dysfunction (MGD) who received one of the 
following medications for the treatment of ocular surface inflammation: loteprednol 
etabonate 0.5% ophthalmic suspension (Lotemax, Bausch & Lomb Inc., Rochester, NY), a 
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combination of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension 
(Zylet, Bausch & Lomb Inc.), or artificial tear (Advanced Eye Relief® Dry Eye 
Environmental Lubricant Eye Drops, Bausch & Lomb Inc.). The study protocol was 
approved by the Human Studies Committee of the Massachusetts Eye and Ear Infirmary, 
Boston, MA, and the research was conducted in accord with the requirements of the Health 
Insurance Portability and Accountability Act (HIPAA) and the tenets of the Declaration of 
Helsinki. This study was registered on clinicaltrials.gov (identifier NCT01456780).
This study included adult patients with MGD-associated DED. All patients had symptoms of 
DED with an Ocular Surface Disease Index (OSDI) score greater than 22, corneal 
fluorescein staining of 4 or more (National Eye Institute [NEI] grading scale, 0–15), and a 
diagnosis of MGD. The latter was diagnosed based on a systematic evaluation of the lid 
margin for obstruction of meibomian glands. Exclusion criteria consisted of the followings: 
use of steroids, antibiotics, or optical soft contact lenses within 2 weeks prior to enrollment; 
any change in the dosage of topical anti-inflammatory medications, other than steroids, or 
oral tetracyclines within 2 weeks prior to enrollment; and the use of isotretinoin within the 
past 6 months. Additional exclusion criteria included history of Stevens-Johnson syndrome 
or mucous membrane pemphigoid, history of herpetic keratitis, active ocular allergies, and 
allergy to aminoglycosides, steroids, or benzalkonium chloride. Potential participants were 
also excluded if they had a known history of glaucoma, an intraocular pressure >22 mmHg 
in either eye, or a known family history of glaucoma in a first degree relative.
Details of the study as well as the potential benefits and harms were thoroughly explained 
for the patients and all signed an informed consent form prior to participation in the study.
Study Treatment
These 60 patients were randomized to receive either loteprednol etabonate 0.5% ophthalmic 
suspension (Lotemax, n=20), a combination of loteprednol etabonate 0.5% and tobramycin 
0.3% ophthalmic suspension (Zylet, n=20), or artificial tear (Advanced Eye Relief® Dry 
Eye Environmental Lubricant Eye Drops, n=20). All these medications were used twice 
daily for both eyes for 4 weeks, after which the study medication was discontinued.
Clinical Evaluation
Each participant had 3 clinic visits: before starting the study medication (baseline), after 4 
weeks (range, ± 7 days) of treatment, and 4 weeks (range, ± 10 days) after discontinuation 
of the treatment (8 weeks after enrollment into the study). During each visit, all participants 
had a complete masked ophthalmic evaluation, which included the following: assessment of 
symptoms using OSDI as well as Symptom Assessment in Dry Eye (SANDE) 
questionnaires; measurement of the best corrected visual acuity and intraocular pressure; 
slit-lamp biomicroscopy to assess corneal fluorescein staining (NEI scale, 0–15), 
conjunctival staining with lissamine green (NEI scale, 0–18), tear break-up time (TBUT), 
and Schirmer’s test with anesthesia.
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In Vivo Confocal Microscopy
In this study, in vivo confocal microscopy (IVCM) was used to measure the corneal subbasal 
nerve fiber length (SNFL) before starting the treatment as well as after 4 weeks of therapy. 
All participants underwent laser IVCM of the central cornea in both eyes using Heidelberg 
Retina Tomograph 3 with the Rostock Cornea Module (Heidelberg Engineering, Heidelberg, 
Germany), as described before.23 This IVCM machine, which employs a 670-nm red 
wavelength diode laser, provides a magnification of 800 times and a lateral resolution of 1 
μm. It obtains digital images at a rate of 3 frames per second, with 100 images per sequence. 
Each image represents a coronal section of 384 × 384 pixels which is equivalent to 400 × 
400 μm of the cornea. A total of three to five sequence scans were obtained from the full-
thickness of the central cornea of eye, with at least 2 sequence scans focused on the 
subepithelial area and the subbasal nerve plexus, usually at a depth of 50–80 μm. The 
images from subepithelial layer of the cornea were utilized to measure SNFL. For each eye, 
three most representative images of the subepithelial layer were chosen for the analysis.
To measure SNFL, the subbasal nerve fibers were traced using NeuronJ (http://
www.imagescience.org/meijering/software/neuronj/), which is a semi-automated nerve 
analysis plug-in of ImageJ (National Institutes of Health, USA). The SNFL was defined as 
the total length of all nerve fibers traced per a 0.16-mm2 image, which was then expressed 
as mm/mm2. To avoid subjective bias, two masked observers measured SNFL 
independently. The mean value of both observers was calculated, and for each patient the 
average of the SNFL values of both eyes was used for further analysis.
To compare the results of IVCM in DED patients to a normal group, the data from 27 age-
matched normal controls were used who did not have any sign or symptoms of DED. The 
SNFL measurement was done in the central cornea of both eyes of these individuals using 
IVCM, as described above. The SNFL measurements in the control group were used to 
define a cut-off point for having a low or near-normal SNFL. For this purpose, the cut-off 
point was considered as the mean value of SNFL in controls minus two standard deviations. 
Based on this cut-off point, DED patients in each of 3 treatment groups were divided into 2 
subgroups, those with low baseline SNFL and those with near-normal baseline SNFL.
Statistical Analysis
Statistical analysis was performed with SPSS for Windows version 21 (SPSS Inc., Chicago, 
IL). For each variable, except for the symptoms, patient’s data were calculated by averaging 
the scores from both eyes. The differences in each variable among the 3 treatment groups 
were compared with chi-square for the qualitative variables and the analysis of variance 
(ANOVA) with Bonferroni correction for quantitative variables. Repeated measure ANOVA 
was also used to compare the changes in each quantitative variable during 8 weeks of the 
study within each group. The differences between the subgroups of near-normal or low 
baseline SNFL were analyzed with independent sample t test. Data normality was verified 
using Shapiro-Wilk test. Two-sided P value of less than 0.05 was considered as statistically 
significant for all comparisons.
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RESULTS
This study included 60 patients with MGD-associated DED who were equally randomized 
into 3 treatment groups. Out of these, 6 patients were either withdrawn or lost to follow-up 
prior to the 4-week visit. Furthermore, 3 additional subjects, one in each group, did not 
complete the 8-week visit. Therefore, 54 patients completed 4-week visit and enrolled in the 
analysis with 20 in the artificial tear group, 17 in the loteprednol etabonate group, and 17 in 
the loteprednol etabonate/tobramycin group. As has been demonstrated in Table 1, there 
were no significant differences among the three groups in terms of age, gender, and dry eye 
signs or symptoms, except for SANDE frequency which was higher in the loteprednol 
etabonate/tobramycin group.
Although there was no significant difference in SNFL among the 3 treatment groups (Table 
1), SNFL was significantly lower in patients with DED (17.06 ± 5.78 mm/mm2) compared 
to the age-matched control group (23.68 ± 3.42 mm/mm2, P=0.001). The cut-off point of 
16.84 mm/mm2 was then used to categorize the subjects with DED to those with low 
baseline SNFL (<16.84 mm/mm2, n=25) and those with near-normal baseline SNFL (≥16.84 
mm/mm2, n=29).
The changes in signs and symptoms of DED after 4 weeks of treatment in each group have 
been presented in Tables 2–4. In the artificial tear group, although no significant 
improvement of any sign and symptom was noted in the subgroup with low baseline SNFL, 
there were significant improvements in the scores of SANDE frequency, SANDE severity, 
OSDI as well as corneal fluorescein staining in the subgroup with near-normal baseline 
SNFL (Table 2). In the subjects treated with loteprednol etabonate, the subgroup with low 
baseline SNFL did not show a significant improvement in any sign or symptom; however, 
those with near-normal baseline SNFL demonstrated significant improvements in SANDE 
severity and corneal fluorescein scores (Table 3). In the loteprednol etabonate/tobramycin 
group, no significant change was evident in any sign or symptom in either subgroups of low 
or near-normal baseline SNFL (Table 4).
Table 5 shows the changes in SNFL after 4 weeks of treatment in each group. Although the 
subjects in the artificial tear group did not demonstrate any significant change in mean 
SNFL, there were significant increases in mean SNFL in loteprednol etabonate and 
loteprednol etabonate/tobramycin groups (P=0.04 for both). During 4 weeks of follow-up 
after stopping the treatment, there were no significant changes in any sign or symptom in 
either subgroups of low or near-normal baseline SNFL in all treatment groups (Fig. 1).
DISCUSSION
This prospective, double-masked, randomized clinical trial showed that in subjects with 
MGD-associated DED who were treated with artificial tears or loteprednol etabonate, only 
subgroup with near-normal baseline SNFL demonstrated significant improvement in 
symptoms and corneal fluorescein staining. In contrast, there was no significant 
improvement after treatment in patients with low baseline SNFL. This SNFL-dependent 
differential response to DED treatment may, in part, explain the variability of patients’ 
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response to therapeutic modalities, which is commonly seen in clinical practice. If 
confirmed in additional larger studies, subject enrollment based on SNFL may assist in 
improving the predictability of response to therapy in future clinical trials for DED.
This study included 54 subjects with MGD-associated DED who also had a low mean 
Schirmer’s test values (Table 1), implying the presence of mixed-mechanism DED with both 
MGD and aqueous tear deficiency playing a role in disease pathogenesis. Compared to an 
age-matched control group, the patients had significantly lower SNFL (23.68 ± 3.42 versus 
17.06 ± 5.78 mm/mm2, P=0.001), as has been demonstrated before.15–22 Although 
morphologic changes in subbasal nerves, such as increased tortuosity, reflectivity, bead-like 
formation, have previously been reported in DED,15–22 these changes were not evaluated in 
this study, as there is no clear consensus on their quantification. On the other hand, an 
arbitrary cut-off point of mean minus 2 standard deviations of SNFL in the controls was 
used to categorize DED patients into those with low SNFL (<16.84 mm/mm2) and those 
with near-normal SNFL (≥16.84 mm/mm2).
Interestingly, in subjects treated with artificial tear or loteprednol etabonate, there was no 
statistically significant improvement in signs or symptoms after 4 weeks of treatment in the 
subgroups of low baseline SNFL (Tables 2 and 3). However, the subgroups with near-
normal baseline SNFL showed remarkable improvement in some symptom scores and 
corneal fluorescein staining, but no other DED signs. This may demonstrate a possible 
prognostic effect of corneal SNFL on the DED response to therapeutic modalities and thus 
may, in part, explain the individual variability in DED management trials.
Nerves have been shown to play a substantial role in the corneal epithelial homeostasis,11 
and loss of corneal nerves has been associated with compromised corneal epithelial health, 
which is well exemplified in neurotrophic keratopathy.14,24 In DED, reduced corneal nerves 
compared to the controls have been reported in most studies,15–22 but not all.25–27 In 
addition, corneal sensation has been demonstrated to be increased26,28 or decreased16,29,30 
in DED. These variations may be due to different subtypes of DED or different stages of the 
disease.31 We speculate that subjects with near-normal SNFL might have more functionally 
intact nerve endings, which may “sense” the improved ocular surface environment after the 
treatment, thus explaining the correlation between nerve density and improved symptoms. 
On the other hand, patients with severely damaged corneal nerves may not detect the post-
treatment improvement in the ocular surface to the same degree. Improved corneal 
fluorescein staining after treatment in patients with near-normal baseline SNFL may also be 
attributed to the trophic support of the corneal nerves, which may help the renewal of a 
normal epithelium during the therapy. Future studies are certainly required to determine the 
mechanism by which higher baseline SNFL results in better outcomes of DED treatment.
Although the combination of loteprednol etabonate/tobramycin has been shown to be 
effective in treatment of blepharokeratoconjunctivitis,32–34 our study did not reveal any 
significant change in signs and symptoms of MGD-associated DED after 4 weeks of 
treatment with this combination in either subgroup of low or near-normal baseline SNFL 
(Table 4), which might, in part, be due to the potential toxicity of tobramycin component.35 
Furthermore, in this study the individuals with near-normal baseline SNFL who were treated 
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with loteprednol etabonate had improvement in fewer symptom scores than those who 
received artificial tears (Tables 2 and 3). Similarly, Pflugfelder and colleagues reported a 
significant reduction of symptoms after using loteprednol four times daily for 4 weeks, 
which was comparable to the placebo.8
At the IVCM level, our study revealed a significant increase in SNFL after treatment with 
loteprednol etabonate and loteprednol etabonate/tobramycin, but not in the artificial tear 
group (Table 5) despite the lack of clinical improvement in loteprednol/tobramycin group. It 
may thus be speculated that the anti-inflammatory regimen used in our study, although 
sufficient to induce cellular changes, was not sufficient to produce clinically noticeable 
improvement. Therefore, treatment with longer duration and/or higher dose of anti-
inflammatory medications may be necessary to achieve the clinical improvement in 
DED.36,37
In conclusion, our study revealed that response of DED to the treatment may be dependent 
on the individual patient’s SNFL. Those with near-normal SNFL may have better response 
to DED therapy. This may help have a better predictability of patient’s outcome in DED 
clinical trials.
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Fig. 1. 
Changes in symptoms and signs in the subgroups with low or near-normal baseline subbasal 
nerve fiber length (SNFL) after 4 weeks of treatment with artificial tears, loteprednol 
etabonate, and loteprednol etabonate/tobramycin as well as during 4 weeks after stopping 
the treatment.
Kheirkhah et al. Page 10
Ophthalmology. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kheirkhah et al. Page 11
Table 1
Clinical characteristics and subbasal nerve fiber length (SNFL) in all treatment groups at the baseline.
Artificial Tear (n=20) Loteprednol Etabonate (n=17) Loteprednol Etabonate/Tobramycin (n=17) P value
Age (years) 57 ± 12 52 ± 12 55 ± 13 0.48
Gender (F/M) 15/5 9/8 8/9 0.18
OSDI 57.0 ± 21.3 52.0 ± 22.6 59.7 ± 18.0 0.55
SANDE Frequency 68.1 ± 17.8 60.9 ± 19.4 77.8 ± 14.2 0.02
SANDE Severity 64.2 ± 19.5 58.1 ± 19.6 67.0 ± 19.8 0.41
Corneal Fluorescein 
Staining (NEI scale)
6.1 ± 2.0 6.6 ± 2.5 6.8 ± 2.6 0.67
Tear Break-up Time 
(seconds)
3.7 ± 2.1 2.9 ± 1.5 2.8 ± 2.2 0.31
Conjunctival 
Lissamine Green 
Staining (NEI scale)
1.9 ± 1.4 3.3 ± 3.7 2.4 ± 2.2 0.23
Schirmer’s Test (mm) 4.8 ± 3.7 5.8 ± 6.1 5.7 ± 7.3 0.83
Subbasal Nerve Fiber 
Length (mm/mm2)
18.4 ± 4.8 15.5 ± 7.0 17.1 ± 5.5 0.33
F: Female, M: male.
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Table 5
Changes in subbasal nerve fiber length (SNFL) after 4 weeks of treatment in different groups.
Subbasal Nerve Fiber Length (mm/mm2)
Baseline 4 Weeks P value
Artificial Tear 18.4 ± 4.8 19.1 ± 5.4 0.23
Loteprednol Etabonate 15.5 ± 7.0 17.4 ± 5.2 0.04
Loteprednol Etabonate/Tobramycin 17.1 ± 5.5 19.1 ± 8.2 0.04
Ophthalmology. Author manuscript; available in PMC 2016 April 01.
